Cite
Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study.
MLA
van de Sande, Nienke, et al. “Tear Biomarkers for Alzheimer’s Disease Screening and Diagnosis (the TearAD Study): Design and Rationale of an Observational Longitudinal Multicenter Study.” BMC Neurology, vol. 23, no. 1, Aug. 2023, pp. 1–7. EBSCOhost, https://doi.org/10.1186/s12883-023-03335-y.
APA
van de Sande, N., Ramakers, I. H. G. B., Visser, P. J., Verhey, F. R. J., Verbraak, F. D., Bouwman, F. H., Berendschot, T. T. J. M., Nuijts, R. M. M. A., Webers, C. A. B., & Gijs, M. (2023). Tear biomarkers for Alzheimer’s disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study. BMC Neurology, 23(1), 1–7. https://doi.org/10.1186/s12883-023-03335-y
Chicago
van de Sande, Nienke, Inez H. G. B. Ramakers, Pieter Jelle Visser, Frans R. J. Verhey, Frank D. Verbraak, Femke H. Bouwman, Tos T. J. M. Berendschot, Rudy M. M. A. Nuijts, Carroll A. B. Webers, and Marlies Gijs. 2023. “Tear Biomarkers for Alzheimer’s Disease Screening and Diagnosis (the TearAD Study): Design and Rationale of an Observational Longitudinal Multicenter Study.” BMC Neurology 23 (1): 1–7. doi:10.1186/s12883-023-03335-y.